Fundraisings and IPOs

* On July 9, 2013, uniQure has announced collaboration agreements with Chiesi Farmaceutici SpA for the commercialization of Glybera®, the first gene therapy to receive regulatory approval in Europe, as well as the co-development of a gene therapy for hemophilia B. In connection with this transaction, uniQure has received € 17 million ($ 21.8 million) in collaboration financing and € 14 million ($ 18 million) in equity financing from Chiesi. This investment by Chiesi has resulted in the conversion into equity of the previously announced  € 14.1 million ($ 18.1 million) investment led by Coller Capital (London, UK) with participation by existing investors.
* On May 14, 2013, uniQure, a human gene therapy company, has announced it has successfully raised a total of € 14.1 million in new investment led by Coller Capital (London, UK) with participation by other existing investors. uniQure raised € 13.5 million in convertible debt led by Coller Capital; other existing investors Forbion Capital Partners, Gilde Healthcare Partners, Lupus Alpha and Grupo Netco also participated. The convertible debt matures on December 31, 2014, the conversion price is set by reference to a modest discount to the price of the next equity round; currently the conversion price is expected to be in the region of €2.00/share. An additional € 0.6 million in new equity funding was invested by staff and persons directly related with the company.